๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University104 First Affiliated Hospital of Zhejiang University103 AstraZeneca76 Zhejiang Cancer Hospital63
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hangzhou

1812 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Neoadjuvant SBRT in Localized Advanced HNSCC
NCT06306846Head and Neck Squamous Carcinoma
Jiang Feng
Phase 2
81
Hangzhou
2023-10-01
Recruiting
A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
NCT06086197Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory
Zhejiang Cancer Hospital
Phase 2
41
Hangzhou
2023-10-01
Not yet open
Canagliflozin With Gemcitabine in Pancreatic Carcinoma
NCT05903703Pancreatic Cancer
Zhang Xiaofeng,MD
Not applicable
20
Hangzhou
2023-10-01
Not yet open
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
NCT05860907Breast Cancer Stage IV
Fudan University
Phase 4
384
Shijiazhuang, Zhengzhou, Changsha, Nantong, Yangzhou, Shanghai, Hangzhou, Jiaxin
2023-10
Recruiting
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
NCT06055816Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
40
Hangzhou
2023-09-28
Recruiting
To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
NCT05997602Langerhans Cell Histiocytosis, LCH
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2
56
Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Chengdu, Hangzhou
2023-09-28
Recruiting
Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study
NCT06114784Severe Pneumonia
First Affiliated Hospital of Zhejiang University
Observational
2,000
Hangzhou, Huzhou, Jiaxing, Lanxi, Lishui, Pinghu, Taizhou, Wenzhou
2023-09-25
Recruiting
A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors
NCT05957536HER-2 Positive Advanced Solid Tumors
D3 Bio (Wuxi) Co., Ltd
Phase 1
128
Harbin, Shanghai, Hangzhou
2023-09-19
Recruiting
A Cohort Study of Uterine Malignancies
NCT05635123Cervical Cancer, Endometrial Cancer
Women's Hospital School Of Medicine Zhejiang University
Observational
6,200
Hangzhou
2023-09-15
Active, closed
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 3
687
Baoji, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2023-09-14
Active, closed
Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth
NCT05698394Prenatal Depression, Ketamine, Postpartum Depression
Peking University First Hospital
Phase 4
364
Changsha, Nanjing, Hangzhou, Beijing
2023-09-09
Recruiting
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms
NCT06026800Digestive System Neoplasms
Sir Run Run Shaw Hospital
Phase 1
20
Hangzhou
2023-09-08
Recruiting
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
NCT06026774Digestive System Neoplasms
Sir Run Run Shaw Hospital
Phase 1
20
Hangzhou
2023-09-08
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
230
Baoding, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan
2023-09-08
Recruiting
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms
NCT06019702Digestive System Neoplasms
Sir Run Run Shaw Hospital
Phase 1
20
Hangzhou
2023-09-08
Active, closed
A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis
NCT06474416Herpes Simplex Virus Type I Stromal Keratitis
Shanghai BDgene Co., Ltd.
Phase 1
16
Shanghai, Hangzhou, Wenzhou
2023-09-04
Active, closed
Clinical Comparison of On1 Two-stage Abutment With One-stage Abutment on Different Implant Neck Design
NCT06022042Implant Site Reaction
Yi Zhou
Not applicable
180
Hangzhou
2023-09-01
Recruiting
Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma
NCT05823311Advanced Cholangiocarcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
80
Hangzhou
2023-09-01
Not yet open
Effectiveness of Ketogenic Diet in MELAS Syndrome
NCT06013397MELAS Syndrome, Ketogenic Dieting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
100
Hangzhou
2023-09-01
Recruiting
AK104 for Recurrent or Metastatic Vulvar Cancer
NCT05932212Vulvar Cancer
Akeso
Phase 2
20
Fuzhou, Guangzhou, Shijiangzhuang, Shenyang, Tianjin, Hangzhou
2023-08-25
Active, closed
Study of XGEVAยฎ (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
NCT04586660Giant Cell Tumor of Bone
Amgen
Phase 4
36
Beijing, Fuzhou, Guangzhou, Harbin, Xi'an, Hangzhou
2023-08-17
Recruiting
Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus
NCT05988216Systemic Lupus Erythematosus (SLE)
Bioray Laboratories
Not applicable
12
Hangzhou
2023-08-14
Recruiting
Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
NCT05905172Liver Fibrosis
Beijing Continent Pharmaceutical Co, Ltd.
Phase 3
248
Beijing, Shanghai, Bengbu, Changsha, Chongqing, Guizhou, Hangzhou, Henan
2023-08-12
Recruiting
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
NCT06043466Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1
30
Hangzhou
2023-08-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Beijing, Cangzhou Shi, Shijiazhuang, Wuxi, Changzhou, Chengdu, Guangzhou, Hangzhou
2023-08-08
Active, closed
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications
Sun Yat-sen University
Phase 3
474
Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou
2023-08-08
Active, closed
CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)
NCT05896137Primary Sclerosing Cholangitis
Cascade Pharmaceuticals, Inc
Phase 2
50
Hefei, Beijing, Wuhan, Changsha, Changchun, Jinan, Shanghai, Hangzhou
2023-08-07
Active, closed
Auxiliary Anesthesia Technique for Extracting Advanced Hemodynamic Parameters Based on Peripheral Arterial Waveform Photography
NCT05961358Anesthesia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
150
Hangzhou
2023-08-01
Active, closed
A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
NCT06044350Optic Neuromyelitis Spectrum Disease
Bio-Thera Solutions
Phase 2
162
Baotou, Beijing, Changsha, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou
2023-08-01
Recruiting
Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology
NCT06388161Epilepsy, Encephalitis Autoimmune
Shen Chun-Hong
Observational
300
Hangzhou
2023-08-01
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
GlaxoSmithKline
Phase 3
892
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2023-08-01
Recruiting
Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer
NCT05914389Colon Neoplasm
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
100
Hangzhou
2023-08
Not yet open
VitaFlowยฎ Transcatheter Aortic Valve Replacement System Pre-market Trial Long Term Follow Up ๏ผˆVITAL๏ผ‰
NCT05977257Aortic Valve Disease, Aortic Valve Stenosis
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Observational
89
Beijing, Chengdu, Hangzhou, Shanghai
2023-07-30
Not yet open
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05970627Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-07-28
Recruiting
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
NCT06227117Breast Cancer
RemeGen Co., Ltd.
Phase 2
120
Changsha, Shanghai, Tianjin, Hangzhou
2023-07-27
Recruiting
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC
NCT07136285SCLC, Extensive Stage
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
Phase 1/2
27
Hangzhou, Shanghai
2023-07-24
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Incyte Corporation
Phase 1
570
Beijing, Hangzhou
2023-07-24
Recruiting
The PRECISION-T2D Study: Precision Nutrition Study for Type 2 Diabetes
NCT05885828Type 2 Diabetes
Westlake University
Not applicable
200
Hangzhou
2023-07-17
Active, closed
A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
NCT05943795Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
589
Guangzhou, Hangzhou
2023-07-14
Active, closed
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
NCT05904379Advanced Non-small-cell Lung Cancer
Akeso
Phase 1/2
233
Hangzhou, Shanghai
2023-07-13
Recruiting
A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer
NCT05911217Pancreatic Cancer
CARsgen Therapeutics Co., Ltd.
Phase 1
20
Beijing, Zhengzhou, Wuhan, Changsha, Shanghai, Xian, Hangzhou
2023-07-11
Recruiting
A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
NCT05886920Advanced Solid Tumors With MAPK Pathway Mutations
D3 Bio (Wuxi) Co., Ltd
Phase 1/2
67
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu, Hangzhou
2023-07-10
Recruiting
Metastatic Nasopharyngeal Carcinoma
NCT06886347Metastatic Nasopharyngeal Carcinoma
Chen Xiaozhong
Phase 1
47
Hangzhou
2023-07-07
Active, closed
Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors
NCT05914376Advanced Solid Tumors
Hangzhou Converd Co., Ltd.
Phase 1
24
Hangzhou, Shanghai
2023-07-05
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
Taiho Oncology, Inc.
Phase 2
120
Guangzhou, Harbin, Nanjing, Changchun, Jinan, Shanghai, Chengdu, Hangzhou
2023-07-05
Recruiting
Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
NCT05920863Hepatocellular Carcinoma, Lenvatinib, Tislelizumab, TACE
Zhejiang Cancer Hospital
Phase 2
35
Hangzhou
2023-07-01
Recruiting
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
NCT05914545Advanced and Metastatic Solid Tumor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
121
Hangzhou, Shanghai, Xuzhou
2023-06-21
Recruiting
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
NCT07394374Solid Tumors Harboring NTRK Fusion, NTRK, NTRK Gene Fusion, NTRK Fusion Positive
Cullgen (Shanghai),Inc
Phase 1/2
42
Beijing, Chengdu, Guangzhou, Hangzhou, Taiyuan
2023-06-20
Active, closed
Application of Sticky Bone and Bio-Oss Collagen in Alveolar Ridge Preservation
NCT05902689Alveolar Bone Resorption
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
42
Hangzhou
2023-06-15
Recruiting
Revascularization Effect on CSVD Burden in Carotid Artery Stenosis
NCT06031610Carotid Artery Stenosis, Cerebral Small Vessel Diseases
Zhejiang Provincial People's Hospital
Observational
1,000
Hangzhou
2023-06-10
Recruiting
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
NCT05830123Osteosarcoma, Sarcoma
Hansoh BioMedical R&D Company
Phase 2
170
Beijing, Changsha, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin, Zhengzhou
2023-06-08
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT05646862Breast Cancer
Hoffmann-La Roche
Phase 3
420
Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang
2023-06-07
Active, closed
Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug
NCT05793307Pompe Disease Infantile-Onset
GeneCradle Inc
Phase 1/2
16
Beijing, Changsha, Hangzhou, Zhengzhou
2023-06-02
Recruiting
Exploratory Research on Constructing a Computational Biological Model Based on NGS for MRD After Breast Cancer Surgery
NCT06595966Breast Cancer, Measurable Residual Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
80
Hangzhou
2023-06-01
Active, closed
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
NCT05844150SCLC
Biotheus Inc.
Phase 2
50
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan
2023-06-01
Active, closed
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
ArriVent BioPharma, Inc.
Phase 3
398
Beijing, Meizhou, Xuhui, Hangzhou, Cangzhou, Shushan, Zhengzhou, Changchun
2023-06-01
Recruiting
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
NCT05862285Cancer
Hoffmann-La Roche
Phase 3
100
Wuhan, XI 'an City, Shaanxi Province, Shanghai, Beijing, Changchun, Chengdu, Guangzhou, Hangzhou
2023-06-01
Recruiting
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05729646Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency
Yu jiren
Phase 2
90
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-31
By invitation
A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)
NCT06186804cGvHD
Abbisko Therapeutics Co, Ltd
Phase 2
64
Beijing, Chongqing, Fuzhou, Guangzhou, Zhujiang, Wuhan, Hangzhou, Suzhou
2023-05-30
Recruiting
SG1906 for CLDN18.2-Positive Solid Tumors
NCT05857332Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
60
Beijing, Xiamen, Guangzhou, Zhengzhou, Shenyang, Taiyuan, Hangzhou
2023-05-30
Active, closed
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05715931Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-30
Recruiting
Early Body Temperature Targets and Relationship With Prognosis in Patients With Heat Stroke
NCT05921682Heat Stroke
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
100
Yiwu, Dongyang, Hangzhou, Jinhua, Lanxi
2023-05-28
Recruiting
Non-inferiority Study of the Effect of Non-cooling Blanket on Body Temperature in Patients With Heat Stroke
NCT05923931Heat Stroke
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
126
Guli, Yiwu, Dongyang, Hangzhou, Jinhua, Lanxi
2023-05-28
Recruiting
A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China
NCT05886114Cognitive Impairment, Alzheimer Disease, Vascular Cognitive Impairment, Dement
Zhejiang University
Not applicable
1,200
Hangzhou
2023-05-28
Recruiting
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
NCT05859750Pancreatic Cancer
Akeso
Phase 2
78
Beijing, Guangzhou, Wuhan, Jinan, Shanghai, Hangzhou
2023-05-25
Active, closed
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
NCT05687890Diabetic Kidney Disease, IgA Nephropathy
Biocity Biopharmaceutics Co., Ltd.
Phase 2
255
Hangzhou
2023-05-23
Recruiting
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
NCT05836948Advanced Solid Tumor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
174
Hangzhou
2023-05-18
Recruiting
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Recruiting
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567Ulcerative Colitis, Crohn's Disease
Takeda
Phase 3
240
Beijing, Zhengzhou, Changsha, Shanghai, Hangzhou
2023-05-16
Active, closed
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
NCT05882513NSCLC, Neoadjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
36
Hangzhou
2023-05-16
Recruiting
A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
NCT05837052Unresectable Lung Non-Small Cell Carcinoma
Zhejiang University
Phase 2
49
Hangzhou
2023-05-15
Recruiting
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ๏ผšA Single-arm, Prospective, Phase II Trial
NCT05862168Oral Squamous Cell Carcinoma
Weijia Fang, MD
Phase 2
30
Hangzhou
2023-05-08
Active, closed
Skin Microbiome of Chinese Population Cohort Study
NCT05804851Skin Microbiome
Westlake University
Observational
237
Hangzhou
2023-05-08
Recruiting
GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence
NCT05557578Intrahepatic Cholangiocarcinoma
Zhejiang Cancer Hospital
Phase 2
20
Hangzhou, Hanzhou
2023-05-05
Active, closed
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
NCT05658003Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Phase 2
63
Wuhan, Nanjing, Shenyang, Xian, Chengdu, Hangzhou, Beijing, Guangzhou
2023-05-05
Not yet open
Peritoneal Lavage on the Incidence of Pancreatic Fistula and Related Complications After Pancreatoduodenectomy
NCT05657366Pancreatic Fistula, Pancreaticoduodenal; Fistula
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
260
Hangzhou
2023-05-01
Recruiting
18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
NCT06813742Pheochromocytoma
First Affiliated Hospital of Zhejiang University
Observational
80
Hangzhou
2023-05-01
Recruiting
Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
NCT05596630Carcinoma; Hepatocellular
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
40
Hangzhou
2023-05-01
Recruiting
Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) Diet in Patients With Intracranial / Carotid Stenosis
NCT05922137Cognitive Decline, Cognitive Change, Stenosis, Dementia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
120
Hangzhou
2023-05-01
Recruiting
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
NCT05827835Hematologic Diseases, Neoplasms
Zhejiang University
Phase 1/2
30
Hangzhou
2023-04-30
Recruiting
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
NCT05741359Non-hodgkin Lymphoma,B Cell
Bioray Laboratories
Phase 1
18
Wuhan, Tianjin, Hangzhou
2023-04-25
Recruiting
Effect of Gut Microbiome Intervention on Aging Via Oral FMT
NCT05598112Aging, Frailty
Chinese Academy of Medical Sciences, Fuwai Hospital
Phase EARLY_PHASE1
210
Beijing, Shanghai, Hangzhou
2023-04-24
Active, closed
Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05813626Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
89
Hangzhou
2023-04-21
Recruiting
SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors
NCT06562647Treatment Related Cancer, Ovarian Cancer
Cell Origin Biotech (Hangzhou) Co., Ltd.
Not applicable
2
Hangzhou, Linyi
2023-04-12
Active, closed
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906Biochemically Recurrent Prostate Cancer
Bayer
Phase 3
985
Beijing, Wuhan, Changsha, Nanjing, Shanghai, Chengdu, Tianjin, Hangzhou
2023-04-03
Active, closed
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777Dermatitis Atopic
Sanofi
Phase 2
999
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jingzhou
2023-04-03
Not yet open
Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients
NCT05719766Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou, Huzhou, Shanghai, Shaoxing
2023-04-01
Active, closed
Efficacy of taVNS Versus Sham Stimulation in Reduing Depressive Symptoms in Patients With Epilepsy: a Multi-center, Double-blinded, Randomized, 20-week, Parallel-arm, Superiority Study
NCT06794034Depressive Symptoms in Patients With Epilepsy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
158
Hangzhou, Jiaxing, Jinhua, Ningbo, Yiwu
2023-04-01
Recruiting
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma
NCT05752136Rectal Cancer
Sir Run Run Shaw Hospital
Phase 3
108
Hangzhou
2023-04-01
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
614
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-03-29
Active, closed
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
NCT05627557Childhood Idiopathic Nephrotic Syndrome
Hoffmann-La Roche
Phase 3
85
Beijing, Guangzhou, Hangzhou, Wuhan, Xi'an, Zhengzhou
2023-03-29
Recruiting
Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
NCT04937699Acute Coronary Syndrome, Percutaneous Coronary Intervention
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
2,690
Hangzhou
2023-03-28
Recruiting
Safety and Efficacy of Preoperative SBRT and Radical Surgery for Soft Tissue Sarcoma of Extremities
NCT06760221Soft Tissue Sarcoma, Stereotactic Body Radiotherapy, Surgery
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
20
Hangzhou
2023-03-23
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guรฉrin (BCG) in Participants With BCG-naรฏve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
Janssen Research & Development, LLC
Phase 3
1,135
Beijing, Changchun, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou
2023-03-23
Active, closed
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
NCT05744427Advanced Solid Tumor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Haโ€™erbin, Hefei, Jinan
2023-03-15
Recruiting
Effect of the Combined Programme on Perioperative Anaemia๏ผˆCPPA๏ผ‰
NCT05353348Patient Blood Management, Cardiac Surgery, Iron Deficiency Anemia
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
110
Hangzhou
2023-03-15
Recruiting
BPH Global Registry
NCT05543200Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Sociรฉtรฉ Internationale d'Urologie
Observational
7,500
Hangzhou
2023-03-13
Active, closed
Energy Metabolism Profiles Over Weight-loss and Eating Responses
NCT05785221Homeostasis, Metabolism and Nutrition Disorder, Healthy, Obesity
Chinese Academy of Sciences
Not applicable
117
Hangzhou
2023-03-02
Recruiting
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
NCT05668403Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 1
52
Zhengzhou, Shijiazhuang, Hangzhou, Beijing, Shanghai
2023-03-02
Not yet open
Study of Telitacicept in Patients With Refractory IgA Nephropathy
NCT05596708IgA Nephropathy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2/3
40
Hangzhou
2023-03-01
Rows per page Showing 1301–1400 of 1812
Previous 12 13 14 15 16 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=14

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,812 of those studies with a site in Hangzhou.

How many clinical trials are recruiting in Hangzhou?

1,096 of the 1,812 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 300 have not yet opened recruitment, 372 are active but closed to new participants, and 44 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.